EMA Authorised: Instanyl (Fentanyl citrate) — Istituto Gentili S.r.l.

View source ↗

Summary

The EMA has authorised Instanyl (fentanyl citrate) by Istituto Gentili S.r.l. for the management of pain, including cancer-related pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Instanyl (Fentanyl citrate)

Snippet

Status: Authorised. Therapeutic area: Pain;Cancer. MAH: Istituto Gentili S.r.l.. Decision date: 12/08/2025